Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 64-68 |
| Journal | Australian Family Physician |
| Volume | 44 |
| Issue number | 1 |
| Publication status | Published - 2015 |
Fingerprint
Cite this
}
Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge. / Munro, A.; Codde, J.P.; Semmens, J.B.; Leung, Yee; Spilsbury, K.; Williams, V.; Steel, N.; Cohen, Paul; Pavicic, H.; Westoby, V.; O'Leary, P.C.
In: Australian Family Physician, Vol. 44, No. 1, 2015, p. 64-68.Research output: Contribution to journal › Article
TY - JOUR
T1 - Utilisation of co-testing (human papillomavirus DNA testing and cervical cytology) after treatment of CIN: A survey of GPs' awareness and knowledge
AU - Munro, A.
AU - Codde, J.P.
AU - Semmens, J.B.
AU - Leung, Yee
AU - Spilsbury, K.
AU - Williams, V.
AU - Steel, N.
AU - Cohen, Paul
AU - Pavicic, H.
AU - Westoby, V.
AU - O'Leary, P.C.
PY - 2015
Y1 - 2015
N2 - Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.
AB - Background: Patients have an increased risk of persistent/recurrent cervical disease if they received treatment for a high-grade squamous intraepithelial lesion (HSIL). Consequently, understanding whether co-testing (human papillomavirus [HPV] DNA testing and cervical cytology) is fully utilised by general practitioners (GPs) is paramount. Methods: After consultation with key stakeholders, an anonymous, self-completion questionnaire was developed and disseminated to GPs who had provided cervical cytology. Results: Responses were received from 745 GPs (30.9% response rate). A significant number (34.3%) of GPs were unaware of the use of co-testing (HPV DNA testing and cervical cytology) for the management of patients after HSIL treatment. Additionally, the majority of GPs reported they did not 'always' receive a clear followup plan for patients after treatment of an HSIL. Discussion: GPs require further support and education to ensure successful adoption of co-testing (HPV DNA testing and cervical cytology), specifically, for patients treated for an HSIL.
M3 - Article
VL - 44
SP - 64
EP - 68
JO - Australian Family Physician.
JF - Australian Family Physician.
SN - 0300-8495
IS - 1
ER -